TLR2 and breast carcinoma: When polysaccharide krestin (PSK), a TLR2 agonist was orally consumed in neu-transgenic mice, it significantly inhibited breast cancer growth by its action on the CD8 (+) T-cell and NK cells but not CD4 (+) T-cells (23).